ΠΜΣ Νεοπλασματική Νόσος στον Άνθρωπο: Σύγχρονη Κλινικοπαθολογοανατομική Προσέγγιση και Έρευνα
Library of the School of Health Sciences

2018-07-20

2018

Chatzimatthaiou Pavlina

Ανδρέας Χ. Λάζαρης, Καθηγητής, Ιατρική, ΕΚΠΑ
Νικόλαος Καβαντζάς, Καθηγητής, Ιατρική, ΕΚΠΑ
Ειρήνη Θυμαρά, Επίκουρη Καθηγήτρια, Ιατρική, ΕΚΠΑ

Ογκολογικός χειρισμός ασθενών με ευνοχοάντοχο καρκίνο του προστάτη, μηχανισμοί δράσης φαρμάκων και αποτελέσματα

Greek

Oncological management of patients with castration-resistant prostate cancer, mechanisms action of medicines and results

The prostate is a gland in men, where it can develop cancer like all human organs. Prostate cancer is the second cause of death in men. PSA, which is a glycoprotein and an important biomarker for diagnosis of prostate cancer. Therapies used to treat it are surgery (radical prostatectomy), radiotherapy, hormone therapy and chemotherapy. Hormone therapy is simply a cure for cancer retardation, and after that cancer cells become resistant to androgenic blocking drugs (hormone therapy). This is called beneficial prostate cancer where cancer cells learn to develop without male hormones (testosterone). The two most effective and recent, strong antiandrogens that increase survival time are abiraterone (zytiga) and enzalutamide (MDV3100). The mechanisms of action of these drugs are inhibition of the CYP17 enzyme and inhibition of the androgen receptor, respectively. Radionuclide 223 which has good bone metastasis reduction results, sipuleucel-T immunotherapy, denosumab antibody and docetaxel chemotherapy and cabazitaxel (taxanes) and combination with corticosteroids (prednisone) to reduce side effects have a beneficial effect and are the primary drugs associated with beneficial prostate cancer. It is important the future research on ARV-7 where it is the cause of enzalutamide resistance but also other molecules that will favor the treatment of beneficial prostate cancer.

Health Sciences

Prostate, Castration-resistant ,Enzalutamide, Abiraterone, Hormonotherpy

No

0

Yes

60

60

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/2779030